HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Vorapaxar

HCID 10077130
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
618385-01-6
Standard SMILES
CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1
InChIKey
ZBGXUVOIWDMMJE-QHNZEKIYSA-N
Molecular formula
C29H33FN2O4
Average molar mass
492.6 g/mol
Monoisotopic mass
492.2424357

Overview

Vorapaxar is a carbamate ester that is the ethyl ester of [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethynyl}-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamic acid. A protease-activated receptor-1 antagonist used (as its sulfate salt) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease. It has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke and urgent coronary revascularisation. It has a role as a cardiovascular drug, a platelet aggregation inhibitor and a protease-activated receptor-1 antagonist. It is a carbamate ester, a lactone, a member of pyridines, an organofluorine compound and a naphthofuran. It is a conjugate base of a vorapaxar(1+).

Names & identifiers

Preferred name
Vorapaxar
IUPAC
ethyl N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]-1-methyl-3-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-1H-benzo[f][2]benzofuran-6-yl]carbamate
English name
Vorapaxar
Molecular formula
C29H33FN2O4
Molecular weight
492.58

Names & synonyms

Vorapaxar618385-01-6SCH-530348SCH530348ZCE93644N2CHEBI:82702DTXSID201009336ethyl N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-1-methyl-3-oxo-dodecahydronaphtho[2,3-c]furan-6-yl]carbamatevorapaxarumethyl N-((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(5-(3-fluorophenyl)pyridin-2-yl)ethenyl)-1-methyl-3-oxo-dodecahydronaphtho(2,3-c)furan-6-yl)carbamateethyl N-((3R,3aS,4S,4aR,7R,8aR,9aR)-4-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)ethenyl)-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-naphtho(6,7-c)furan-7-yl)carbamateethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-naphtho[6,7-c]furan-7-yl]carbamate
Show more names
MK-5348Vorapaxar (SCH 530348)[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-carbamic acid ethyl esterCS-2015CS-1663Voarapaxar

Properties

Computed structural propertiesFilling in

XLogP
5.3
Topological polar surface area
77.5 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
6
Rotatable bonds
6
Heavy atoms
36
Formal charge
0
Complexity
821

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Blood and blood forming organs -> Antithrombotic agents

Physicochemical properties

Boiling point
676 · 676.0±55.0 °C(Predicted)
Density
1.24 · 1.24±0.1 g/cm3(Predicted)
storage temp.
-20 ° · Store at -20° C
solubility
24.65 mg/mL · ≥24.65 mg/mL in DMSO; insoluble in H2O; ≥10.64 mg/mL in EtOH with ultrasonic
form
solid
pka
12.49 · 12.49±0.60(Predicted)
color
White to off-white
InChIKey
ZBGXUVOIWDMMJE-QHNZEKIYSA-N
SMILES
C(OCC)(=O)N[C@@H]1CC[C@]2([H])[C@@]([H])(C1)C[C@@]1([H])C(=O)O[C@H](C)[C@@]1([H])[C@H]2/C=C/C1=NC=C(C2=CC=CC(F)=C2)C=C1
FDA UNII
93644 N2 · ZCE93644N2

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H371 (66.7%): May cause damage to organs [Warning Specific target organ toxicity, single exposure]

P260, P264, P270, P273, P308+P316, P319, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 3 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesSTOT SE 2 (66.7%)

Toxicology

Hepatotoxicity · 1 item

Vorapaxar is associated with a low rate of serum enzyme elevations during therapy that was similar to the rate that occurred with placebo or comparator therapies. In a large controlled trial in over 10,000 patients monitored over a 2 year period, ALT elevations above 5 times the upper limit of normal occurred in 1% of vorapaxar vs 1.4% of placebo patients. In pooled analyses of laboratory studies from more than 39,000 patients receiving vorapaxar or placebo, GGT was the only liver test that was abnormal in a higher proportion of patients receiving vorapaxar (3.8%) than placebo (3.3%), and there were no reports of liver related serious adverse events or clinically apparent liver injury. Thus, liver injury from vorapaxar must be rare, if it occurs at all.

Safety data

wgk
WGK 3
Signal word
Warning
Symbol(GHS)
GHS08,GHS09
Storage Class
11 - Combustible Solids

Chemistry & industry

Pharmacology

ATC Code · 2 items

B - Blood and blood forming organs

QB - Blood and blood forming organs

Protein BindingVorapaxar is extensively bound (>99%) to human plasma proteins, such as human serum albumin.
Mechanism of Action · 1 item

Vorapaxar inhibits platelet aggregation through the reversible antagonism of protease-activated receptor 1 (PAR-1), also known as thrombin receptor. PARs are a family of G-protein coupled receptors highly expressed on platelets and activated by serine protease activity of thrombin to mediate thrombotic response. By blocking PAR-1 activating, vorapaxar inhibits thrombin-induced platelet aggregation and thrombin receptor agonist peptide (TRAP)-induced platelet aggregation. Vorapaxar does not inhibit platelet aggregation induced by other agonists such as adenosine diphosphate (ADP), collagen or a thromboxane mimetic.

Biological Half-LifeVorapaxar has an effective half life of 3-4 days and an apparent terminal half life of 8 days.
Metabolism/MetabolitesVorapaxar is metabolized to its major circulating metabolite, M20, and its predominant metabolite excreted into feces, M19, by CYP3A4 and CYP 2J2.
FDA Pharmacological Classification · 5 items

ZCE93644N2

VORAPAXAR

Established Pharmacologic Class [EPC] - Protease-activated Receptor-1 Antagonist

Mechanisms of Action [MoA] - Protease-activated Receptor-1 Antagonists

Vorapaxar is a Protease-activated Receptor-1 Antagonist. The mechanism of action of vorapaxar is as a Protease-activated Receptor-1 Antagonist.

MeSH Pharmacological Classification · 1 item

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
2H5]-Vorapaxar
7-Dihydrocapsaicin
RefChem:56276B01AC26DTXCID801436165Vorapaxar free baseMFCD16038876UNII-ZCE93644N2ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl)carbamateCHEMBL493982

Database identifiers

CAS
618385-01-6
PubChem CID
10077130
DTXSID
DTXSID201009336
ChEMBL
CHEMBL493982
ChEBI
CHEBI:82702
UNII
ZCE93644N2
EC Number
612-523-7
Nikkaji
J2.419.474D、J2.933.500A
ATC code
1 AC26 · B01AC26
UNSPSC Code
12352200 · 12352200
NACRES
77 · NA.77
Symbol(GHS)
8 · GHS08,GHS09
Signal word
Warning
Hazard statements
371 · H371-H410-H373-H400
Precautionary statements
273 · P273-P391-P501-P273-P391-P501-P260-P314-P501-P260-P264-P270-P309+P311-P405-P501
WGK Germany
3 · WGK 3
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
1 Aquatic · Aquatic Acute 1Aquatic Chronic 1
Hazard statements
H371-H410-H373-H400
Hazard Classifications
Aquatic Acute 1Aquatic Chronic 1
Precautionary statements
P273-P391-P501-P273-P391-P501-P260-P314-P501-P260-P264-P270-P309+P311-P405-P501
Absorption, Distribution and Excretion · 3 items

After oral administration, vorapaxar is rapidly absorbed and peak concentrations occur at a median tmax of 1 hour under faster conditions. Vorapaxar may be taken with or without food as ingestion with a high-fat meal did not result in meaningful changes in AUC. The mean absolute bioavailability is 100%.

Vorapaxar is primarily eliminated as its metabolite M19 through the feces (91.5%), and partially eliminated in the urine (8.5%).

424 L

Applications · 2 items

DescriptionVorapaxar is an orally bioavailable competitive antagonist of the proteinase-activated receptor (PAR1; Ki = 8.1 nM), also known as the thrombin receptor. It is selective for PAR1 over other PARs, as well as a number of GPCRs, ion channels, and receptors. It inhibits platelet aggregation induced by thrombin and haTRAP (IC50s = 47 and 25 nM, respectively). Vorapaxar (0.1 mg/kg, i.v.) completely inhibits platelet aggregation in cynomolgus monkeys ex vivo. Formulations containing vorapaxar are used in the prevention of thrombotic cardiovascular events.

UsesVorapaxar (SCH 530348), an antiplatelet agent, is a selective, orally active, and competitive thrombin receptor protease-activated receptor (PAR-1) antagonist (Ki=8.1 nM). Vorapaxar (SCH 530348) inhibits thrombin receptor-activating peptide (TRAP)-induced platelet aggregation in a dose-dependent manner[1].

Additional notes · 1 item

DefinitionChEBI: A carbamate ester that is the ethyl ester of [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethyny }-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamic acid. A protease-activated receptor-1 antagonist used (as its sulfate salt) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction MI) or with peripheral arterial disease. It has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke and urgent coronary revascularisation.